biote Corp. (BTMDW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
biote Corp. (BTMDW) trades at $1.61. biote Corp. operates in the medical practice-building business within the hormone optimization space, offering a platform for practitioners to optimize patient hormone levels. Market cap: $292.88M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for BTMDW: BTMDW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BTMDW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BTMDW: 1/1 perspectives are bearish.
How is this calculated? →biote Corp. (BTMDW) Healthcare & Pipeline Overview
biote Corp. focuses on hormone optimization, providing a platform for certified practitioners to offer bioidentical hormone therapies and dietary supplements. With a market capitalization of $292.88M and a strong gross margin of 71.5%, biote operates within the growing market for personalized healthcare solutions, offering branded supplements and sterile insertion kits.
What Is the Investment Thesis for BTMDW?
biote Corp. presents an interesting investment case within the hormone optimization market. With a market capitalization of $292.88M and a P/E ratio of 1.59, the company demonstrates profitability, supported by a profit margin of 14.1% and a gross margin of 71.5%. Key value drivers include the expansion of its network of Biote-certified practitioners and the increasing demand for personalized hormone therapies. Growth catalysts for biote Corp. include the introduction of new dietary supplements and the expansion into new geographic markets. The company's focus on practitioner training and certification enhances its competitive advantage. Potential risks include regulatory changes in the hormone therapy market and competition from other providers of personalized healthcare solutions. The company's ability to maintain its high gross margins and expand its market share will be critical to its long-term success.
Based on FMP financials and quantitative analysis
BTMDW Key Highlights
- Market Cap of $292.88M indicates a relatively small but established player in the hormone optimization market.
- P/E ratio of 1.59 suggests the company is undervalued compared to its earnings.
- Profit Margin of 14.1% demonstrates the company's ability to generate profit from its revenue.
- Gross Margin of 71.5% indicates strong pricing power and efficient cost management.
- No dividend yield reflects a focus on reinvesting earnings for growth.
Who Are BTMDW's Competitors?
BTMDW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CSSPF NIOX Group Plc | $0.75 | +0.00% | $315.65M | 47 |
| DLHTF Dialogue Health Technologies Inc. | $3.79 | +0.59% | $254.80M | 56 |
| GUERF Guerbet S.A. | $22.25 | +0.00% | $281.03M | 43 |
| HTLZF Hamilton Thorne Ltd. | $1.59 | +0.00% | $245.15M | 53 |
| HYBT Heyu Biological Technology Corporation | $0.35 | -41.67% | $361.36M | 42 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BTMDW's Key Strengths?
- Established platform for hormone optimization.
- Network of Biote-certified practitioners.
- Strong gross margin of 71.5%.
- Proprietary Biote-branded products.
What Are BTMDW's Weaknesses?
- Reliance on Biote-certified practitioners for service delivery.
- Limited geographic diversification.
- Potential regulatory risks in the hormone therapy market.
- Dependence on patient acceptance of hormone therapies.
What Could Drive BTMDW Stock Higher?
- Potential expansion into new geographic markets, increasing revenue streams.
- Continued growth in the network of Biote-certified practitioners, enhancing market reach.
- Introduction of new Biote-branded dietary supplements, expanding product offerings.
- Strategic partnerships with healthcare providers, creating synergistic opportunities.
What Are the Key Risks for BTMDW?
- Negative return on equity (-22.9%) — the business is not currently generating profit on shareholder capital.
- Regulatory changes in the hormone therapy market could impact the company's operations.
- Competition from other providers of hormone therapies may erode market share.
- Negative publicity regarding hormone therapies could affect patient demand.
- Dependence on Biote-certified practitioners for service delivery creates operational risk.
- Limited financial disclosure due to OTC listing increases investment risk.
What Are the Growth Opportunities for BTMDW?
- Expansion of Biote-Certified Practitioner Network: biote Corp. can drive growth by expanding its network of Biote-certified practitioners. This involves increasing the number of practitioners who utilize the Biote platform to offer hormone optimization treatments. The market for hormone therapies is growing, and by expanding its network, Biote can reach a larger patient base. This expansion can be achieved through targeted marketing efforts and partnerships with medical practices. The timeline for this growth opportunity is ongoing, with continuous efforts to recruit and train new practitioners.
- Introduction of New Dietary Supplements: biote Corp. can introduce new Biote-branded dietary supplements to complement its existing product line. This involves developing and marketing new supplements that address specific hormone-related needs. The market for dietary supplements is large and growing, and by introducing new products, Biote can increase its revenue and market share. This growth opportunity can be realized through research and development efforts and strategic partnerships with supplement manufacturers. The timeline for this growth opportunity is ongoing, with continuous efforts to innovate and expand its product offerings.
- Geographic Expansion: biote Corp. can expand its operations into new geographic markets. This involves establishing a presence in regions where the demand for hormone optimization treatments is growing. By expanding geographically, Biote can reach a larger patient base and increase its revenue. This growth opportunity can be realized through strategic partnerships with medical practices and targeted marketing efforts. The timeline for this growth opportunity is ongoing, with continuous efforts to identify and enter new markets.
- Strategic Partnerships: biote Corp. can form strategic partnerships with other healthcare providers and wellness companies. This involves collaborating with organizations that can complement Biote's offerings and expand its reach. By forming strategic partnerships, Biote can access new markets and customer segments. This growth opportunity can be realized through networking and relationship-building efforts. The timeline for this growth opportunity is ongoing, with continuous efforts to identify and establish strategic partnerships.
- Increased Marketing and Awareness: biote Corp. can increase its marketing and awareness efforts to educate consumers about the benefits of hormone optimization. This involves promoting the Biote platform and its offerings through various channels, including digital marketing, social media, and public relations. By increasing awareness, Biote can attract new patients and practitioners to its platform. This growth opportunity can be realized through strategic marketing campaigns and targeted outreach efforts. The timeline for this growth opportunity is ongoing, with continuous efforts to enhance its marketing and awareness initiatives.
What Opportunities Does BTMDW Have?
- Expansion into new geographic markets.
- Introduction of new Biote-branded products.
- Strategic partnerships with healthcare providers.
- Increased marketing and awareness efforts.
What Threats Does BTMDW Face?
- Competition from other providers of hormone therapies.
- Regulatory changes in the hormone therapy market.
- Negative publicity regarding hormone therapies.
- Economic downturn affecting patient spending on elective treatments.
What Are BTMDW's Competitive Advantages?
- Established network of Biote-certified practitioners.
- Proprietary platform for hormone optimization.
- Brand recognition in the hormone therapy market.
What Does BTMDW Do?
biote Corp., founded in 2011 and headquartered in Irving, Texas, operates within the medical practice-building business, specifically focusing on hormone optimization. The company provides a platform for Biote-certified practitioners to address hormone imbalances in their patients through bioidentical hormone therapies and dietary supplements. Biote's offerings include the prescription of bioidentical hormone therapies and the recommendation of dietary supplements to optimize hormone, vitamin, and mineral levels. The company also sells Biote-branded dietary supplements and sterile pellet insertion kits for both men and women. Biote's business model centers around empowering healthcare practitioners to offer personalized hormone optimization treatments. By providing a comprehensive platform, Biote enables practitioners to enhance their practice offerings and cater to the growing demand for hormone-related healthcare solutions. The company's focus on bioidentical hormone therapies and dietary supplements positions it within the broader market for personalized medicine and wellness solutions. With a strong emphasis on practitioner training and certification, Biote ensures that its platform is utilized effectively and safely. The company's commitment to quality and innovation has contributed to its growth within the hormone optimization space. As the demand for personalized healthcare continues to rise, Biote is poised to capitalize on its established platform and expand its reach within the medical community.
What Products and Services Does BTMDW Offer?
- Offers a platform for Biote-certified practitioners.
- Provides bioidentical hormone therapies.
- Recommends dietary supplements to optimize hormone levels.
- Sells Biote-branded dietary supplements.
- Sells sterile pellet insertion kits for men and women.
- Focuses on hormone optimization for patients.
How Does BTMDW Make Money?
- Generates revenue from the sale of Biote-branded dietary supplements.
- Generates revenue from the sale of sterile pellet insertion kits.
- Provides a platform for practitioners, potentially through licensing or subscription fees.
What Industry Does BTMDW Operate In?
biote Corp. operates within the medical care facilities industry, specifically focusing on hormone optimization. The market for personalized hormone therapies is growing, driven by increasing awareness of hormone imbalances and the demand for personalized healthcare solutions. The competitive landscape includes other providers of hormone therapies and dietary supplements. Biote's focus on practitioner training and certification differentiates it from some competitors. The company's success depends on its ability to maintain its competitive advantage and capitalize on the growing demand for personalized hormone optimization treatments.
Who Are BTMDW's Key Customers?
- Biote-certified practitioners.
- Patients seeking hormone optimization treatments.
- Medical practices offering hormone therapies.
Net buyingInsider Activity
Over the past six months, biote Corp. insiders filed 14 SEC Form 4 transactions — 1 sales and 13 purchases. On net that is roughly 1.5M shares acquired (about $2.7M) — insiders putting money in tends to read as conviction.
F-Score 5/9Financial Health
biote Corp.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.60 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -23%Key Financial Metrics
Return on equity for biote Corp. stands at -22.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.5%, showing how much profit it generates from its asset base. BTMDW trades at a trailing price-to-earnings ratio of 4.83, below the Healthcare sector average of ~23x. Its free cash flow yield is 25.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 20.7%, the inverse of the P/E and a quick read on earnings relative to price.
biote Corp. (BTMDW) Valuation Context
Valued at $292.88M, BTMDW is classified as a micro-cap stock.
BTMDW Revenue & Earnings Trend
In Q1 2026, BTMDW generated $44.9M in top-line revenue, marking a sequential decrease of 3.2%. The company recorded net income of $2.3M, with diluted EPS of $0.06. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, BTMDW averaged $0.11 in diluted EPS.
Company Profile
biote Corp. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Irving, US. The company is led by CEO Marc D. Beer. BTMDW has traded publicly since 2022.
BTMDW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the value of their stock.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could attract investor interest.
- Analysts note a growing demand for biotech solutions, positioning Biote Corp. favorably within a booming industry.
- Recent partnerships with established healthcare providers have strengthened market perception, enhancing credibility and potential revenue streams.
Bear Case
- Concerns about regulatory hurdles in the biotech sector have led to increased skepticism among investors, impacting overall sentiment.
- Some community members express doubts about the scalability of Biote's business model, questioning its long-term sustainability.
- Recent market trends show a pullback in biotech investments, which could negatively affect Biote's stock performance.
- Insider selling activity has raised red flags for some investors, leading to a perception of uncertainty about the company's direction.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $45M | $2M | $0.06 |
| Q4 2025 | $46M | $2M | $0.06 |
| Q3 2025 | $48M | $8M | $0.22 |
| Q2 2025 | $49M | $3M | $0.10 |
Based on FMP financials and quantitative analysis
BTMDW Latest News
No recent news available for BTMDW.
BTMDW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BTMDW.
Price Targets
Wall Street price target analysis for BTMDW.
BTMDW MoonshotScore
What does this score mean?
The MoonshotScore rates BTMDW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Marc D. Beer
CEO
Marc D. Beer serves as the CEO of biote Corp. His background includes extensive experience in the healthcare and pharmaceutical industries. Prior to joining biote Corp., Beer held leadership positions at various healthcare companies, where he focused on strategic growth and market expansion. His expertise lies in driving innovation and commercializing healthcare solutions. Beer's educational background includes advanced degrees in business and healthcare management, providing him with a strong foundation for leading biote Corp.
Track Record: Under Marc D. Beer's leadership, biote Corp. has focused on expanding its network of Biote-certified practitioners and introducing new Biote-branded products. He has overseen the company's efforts to increase marketing and awareness of hormone optimization treatments. Key milestones under his tenure include the expansion into new geographic markets and the formation of strategic partnerships with healthcare providers. His strategic decisions have contributed to the company's growth and market position.
BTMDW OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that biote Corp. (BTMDW) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with higher risk profiles due to their limited transparency and potential for speculative trading.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in BTMDW.
- Low trading volume can lead to price volatility and illiquidity.
- The OTC Other tier indicates a higher risk profile compared to stocks listed on major exchanges.
- Potential for speculative trading and market manipulation.
- Regulatory oversight may be limited, increasing the risk of fraud or mismanagement.
- Verify the accuracy and completeness of available financial information.
- Assess the company's business model and competitive position.
- Evaluate the management team and their track record.
- Review the company's regulatory filings and compliance history.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making investment decisions.
- The company has been in operation since 2011.
- biote Corp. operates in the healthcare sector.
- The company has a market capitalization of $292.88M.
- The company has a P/E ratio of 1.59.
- The company has a profit margin of 14.1%.
BTMDW Healthcare Stock FAQ
What does biote Corp. do?
biote Corp. operates in the medical practice-building business within the hormone optimization space. The company provides a platform for Biote-certified practitioners to optimize hormone imbalances in their patients through bioidentical hormone therapies and dietary supplements. It sells Biote-branded dietary supplements and sterile pellet insertion kits. The company focuses on empowering healthcare practitioners to offer personalized hormone optimization treatments, catering to the growing demand for hormone-related healthcare solutions.
What are the main risks for BTMDW?
The main risks for BTMDW include regulatory changes in the hormone therapy market, competition from other providers of hormone therapies, and potential negative publicity regarding hormone therapies. The company's dependence on Biote-certified practitioners for service delivery creates operational risk. Additionally, the limited financial disclosure due to its OTC listing increases investment risk. Investors should carefully consider these risks before investing in BTMDW.
What are the key factors to evaluate for BTMDW?
Evaluate BTMDW on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does BTMDW data refresh on this page?
BTMDW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BTMDW's recent stock price performance?
biote Corp. (BTMDW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established platform for hormone optimization. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BTMDW overvalued or undervalued right now?
Valuing biote Corp. (BTMDW) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BTMDW?
Before investing in biote Corp. (BTMDW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BTMDW to a portfolio?
Key strength of biote Corp. (BTMDW): Established platform for hormone optimization. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis is pending.